KDR and hepatocellular carcinoma: Given the sensitizing effect of miR-34a to the VEGFR TKI sorafenib in hepatocellular carcinoma (HCC) [70], the authors suggest combined treatment of HCC with rubone and sorafenib for this disease [60].